The CD9, CD81, and CD151 EC2 domains bind to the classical RGD-binding site of integrin αvβ3

Jessica Yu, Chia Ying Lee, Chun Austin Changou, Dora M. Cedano-Prieto, Yoko K. Takada, Yoshikazu Takada

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Tetraspanins play important roles in normal (e.g. cell adhesion, motility, activation, and proliferation) and pathological conditions (e.g. metastasis and viral infection). Tetraspanins interact with integrins and regulate integrin functions, but the specifics of tetraspanin-integrin interactions are unclear. Using co-immunoprecipitation with integrins as a sole method to detect interaction between integrins and full-length tetraspanins, it has been proposed that the variable region (helices D and E) of the extracellular-2 (EC2) domain of tetraspanins laterally associates with a non-ligand-binding site of integrins. We describe that, using adhesion assays, the EC2 domain of CD81, CD9, and CD151 bound to integrin αvβ3, and this binding was suppressed by cRGDfV, a specific inhibitor of αvβ3, and antibody 7E3, which is mapped to the ligand-binding site of β3. We also present evidence that the specificity loop of β3 directly bound to the EC2 domains. This suggests that the EC2 domains specifically bind to the classical ligand-binding site of αvβ3. αvβ3 was a more effective receptor for the EC2 domains than the previously known tetraspanin receptors α3β1, α4β1, and α6β1. Docking simulation predicted that the helices A and B of CD81 EC2 bind to the RGD-binding site of αvβ3. Substituting Lys residues at positions 116 and 144/148 of CD81 EC2 in the predicted integrin-binding interface reduced the binding of CD81 EC2 to αvβ3, consistent with the docking model. These findings suggest that, in contrast with previous models, the ligand-binding site of integrin αvβ3, a new tetraspanin receptor, binds to the constant region (helices A and B) of the EC2 domain.

Original languageEnglish
Pages (from-to)589-596
Number of pages8
JournalBiochemical Journal
Volume474
Issue number4
DOIs
Publication statusPublished - Feb 15 2017

Fingerprint

Integrins
Binding Sites
Tetraspanins
Ligands
Cell adhesion
Virus Diseases
Immunoprecipitation
Cell Adhesion
Cell Movement
Assays
Adhesion
Chemical activation
Neoplasm Metastasis
Antibodies

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Yu, J., Lee, C. Y., Changou, C. A., Cedano-Prieto, D. M., Takada, Y. K., & Takada, Y. (2017). The CD9, CD81, and CD151 EC2 domains bind to the classical RGD-binding site of integrin αvβ3. Biochemical Journal, 474(4), 589-596. https://doi.org/10.1042/BCJ20160998

The CD9, CD81, and CD151 EC2 domains bind to the classical RGD-binding site of integrin αvβ3. / Yu, Jessica; Lee, Chia Ying; Changou, Chun Austin; Cedano-Prieto, Dora M.; Takada, Yoko K.; Takada, Yoshikazu.

In: Biochemical Journal, Vol. 474, No. 4, 15.02.2017, p. 589-596.

Research output: Contribution to journalArticle

Yu, J, Lee, CY, Changou, CA, Cedano-Prieto, DM, Takada, YK & Takada, Y 2017, 'The CD9, CD81, and CD151 EC2 domains bind to the classical RGD-binding site of integrin αvβ3', Biochemical Journal, vol. 474, no. 4, pp. 589-596. https://doi.org/10.1042/BCJ20160998
Yu, Jessica ; Lee, Chia Ying ; Changou, Chun Austin ; Cedano-Prieto, Dora M. ; Takada, Yoko K. ; Takada, Yoshikazu. / The CD9, CD81, and CD151 EC2 domains bind to the classical RGD-binding site of integrin αvβ3. In: Biochemical Journal. 2017 ; Vol. 474, No. 4. pp. 589-596.
@article{b7c2e1e7d5e045c38df47dc047a22a65,
title = "The CD9, CD81, and CD151 EC2 domains bind to the classical RGD-binding site of integrin αvβ3",
abstract = "Tetraspanins play important roles in normal (e.g. cell adhesion, motility, activation, and proliferation) and pathological conditions (e.g. metastasis and viral infection). Tetraspanins interact with integrins and regulate integrin functions, but the specifics of tetraspanin-integrin interactions are unclear. Using co-immunoprecipitation with integrins as a sole method to detect interaction between integrins and full-length tetraspanins, it has been proposed that the variable region (helices D and E) of the extracellular-2 (EC2) domain of tetraspanins laterally associates with a non-ligand-binding site of integrins. We describe that, using adhesion assays, the EC2 domain of CD81, CD9, and CD151 bound to integrin αvβ3, and this binding was suppressed by cRGDfV, a specific inhibitor of αvβ3, and antibody 7E3, which is mapped to the ligand-binding site of β3. We also present evidence that the specificity loop of β3 directly bound to the EC2 domains. This suggests that the EC2 domains specifically bind to the classical ligand-binding site of αvβ3. αvβ3 was a more effective receptor for the EC2 domains than the previously known tetraspanin receptors α3β1, α4β1, and α6β1. Docking simulation predicted that the helices A and B of CD81 EC2 bind to the RGD-binding site of αvβ3. Substituting Lys residues at positions 116 and 144/148 of CD81 EC2 in the predicted integrin-binding interface reduced the binding of CD81 EC2 to αvβ3, consistent with the docking model. These findings suggest that, in contrast with previous models, the ligand-binding site of integrin αvβ3, a new tetraspanin receptor, binds to the constant region (helices A and B) of the EC2 domain.",
author = "Jessica Yu and Lee, {Chia Ying} and Changou, {Chun Austin} and Cedano-Prieto, {Dora M.} and Takada, {Yoko K.} and Yoshikazu Takada",
year = "2017",
month = "2",
day = "15",
doi = "10.1042/BCJ20160998",
language = "English",
volume = "474",
pages = "589--596",
journal = "Biochemical Journal",
issn = "0264-6021",
publisher = "Portland Press Ltd.",
number = "4",

}

TY - JOUR

T1 - The CD9, CD81, and CD151 EC2 domains bind to the classical RGD-binding site of integrin αvβ3

AU - Yu, Jessica

AU - Lee, Chia Ying

AU - Changou, Chun Austin

AU - Cedano-Prieto, Dora M.

AU - Takada, Yoko K.

AU - Takada, Yoshikazu

PY - 2017/2/15

Y1 - 2017/2/15

N2 - Tetraspanins play important roles in normal (e.g. cell adhesion, motility, activation, and proliferation) and pathological conditions (e.g. metastasis and viral infection). Tetraspanins interact with integrins and regulate integrin functions, but the specifics of tetraspanin-integrin interactions are unclear. Using co-immunoprecipitation with integrins as a sole method to detect interaction between integrins and full-length tetraspanins, it has been proposed that the variable region (helices D and E) of the extracellular-2 (EC2) domain of tetraspanins laterally associates with a non-ligand-binding site of integrins. We describe that, using adhesion assays, the EC2 domain of CD81, CD9, and CD151 bound to integrin αvβ3, and this binding was suppressed by cRGDfV, a specific inhibitor of αvβ3, and antibody 7E3, which is mapped to the ligand-binding site of β3. We also present evidence that the specificity loop of β3 directly bound to the EC2 domains. This suggests that the EC2 domains specifically bind to the classical ligand-binding site of αvβ3. αvβ3 was a more effective receptor for the EC2 domains than the previously known tetraspanin receptors α3β1, α4β1, and α6β1. Docking simulation predicted that the helices A and B of CD81 EC2 bind to the RGD-binding site of αvβ3. Substituting Lys residues at positions 116 and 144/148 of CD81 EC2 in the predicted integrin-binding interface reduced the binding of CD81 EC2 to αvβ3, consistent with the docking model. These findings suggest that, in contrast with previous models, the ligand-binding site of integrin αvβ3, a new tetraspanin receptor, binds to the constant region (helices A and B) of the EC2 domain.

AB - Tetraspanins play important roles in normal (e.g. cell adhesion, motility, activation, and proliferation) and pathological conditions (e.g. metastasis and viral infection). Tetraspanins interact with integrins and regulate integrin functions, but the specifics of tetraspanin-integrin interactions are unclear. Using co-immunoprecipitation with integrins as a sole method to detect interaction between integrins and full-length tetraspanins, it has been proposed that the variable region (helices D and E) of the extracellular-2 (EC2) domain of tetraspanins laterally associates with a non-ligand-binding site of integrins. We describe that, using adhesion assays, the EC2 domain of CD81, CD9, and CD151 bound to integrin αvβ3, and this binding was suppressed by cRGDfV, a specific inhibitor of αvβ3, and antibody 7E3, which is mapped to the ligand-binding site of β3. We also present evidence that the specificity loop of β3 directly bound to the EC2 domains. This suggests that the EC2 domains specifically bind to the classical ligand-binding site of αvβ3. αvβ3 was a more effective receptor for the EC2 domains than the previously known tetraspanin receptors α3β1, α4β1, and α6β1. Docking simulation predicted that the helices A and B of CD81 EC2 bind to the RGD-binding site of αvβ3. Substituting Lys residues at positions 116 and 144/148 of CD81 EC2 in the predicted integrin-binding interface reduced the binding of CD81 EC2 to αvβ3, consistent with the docking model. These findings suggest that, in contrast with previous models, the ligand-binding site of integrin αvβ3, a new tetraspanin receptor, binds to the constant region (helices A and B) of the EC2 domain.

UR - http://www.scopus.com/inward/record.url?scp=85014610065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014610065&partnerID=8YFLogxK

U2 - 10.1042/BCJ20160998

DO - 10.1042/BCJ20160998

M3 - Article

C2 - 27993971

AN - SCOPUS:85014610065

VL - 474

SP - 589

EP - 596

JO - Biochemical Journal

JF - Biochemical Journal

SN - 0264-6021

IS - 4

ER -